{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:39:50Z","timestamp":1790797190979,"version":"4.1.0"},"reference-count":29,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2022,9,1]]},"abstract":"Importance<\/jats:title>Treatment of newly diagnosed multiple myeloma (NDMM) with a quadruplet regimen consisting of a monoclonal antibody, proteasome inhibitor, immunomodulatory imide, and corticosteroid has been associated with improved progression-free survival (PFS) compared with triplet regimens. The optimal quadruplet combination, and whether this obviates the need for frontline autologous stem cell transplant (ASCT), remains unknown. We evaluated elotuzumab and weekly carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) without ASCT in NDMM.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the efficacy of Elo-KRd using a measurable residual disease (MRD)-adapted design in NDMM regardless of ASCT eligibility.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This multicenter, single-arm, phase 2 study enrolled patients between July 2017 and February 2021. Median follow-up was 29 months.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Twelve to 24 cycles of Elo-KRd; consecutive MRD-negative results at 10\u22126<\/jats:sup> by next-generation sequencing (NGS) after cycles 8 (C8) and 12 determined the duration of Elo-KRd. This was followed by Elo-Rd (no carfilzomib) maintenance therapy until disease progression.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The primary end point was the rate of stringent complete response (sCR) and\/or MRD-negativity (10\u22125<\/jats:sup>) after C8 Elo-KRd. Secondary end points included safety, rate of response, MRD status, PFS, and overall survival (OS). As an exploratory analysis, MRD was assessed using liquid chromatography mass spectrometry (MS) on peripheral blood samples.<\/jats:p><\/jats:sec>Results<\/jats:title>Forty-six patients were enrolled (median age 62 years, 11 [24%] aged &gt;70 years). Overall, 32 (70%) were White, 6 (13%) were Black, 3 (6%) were more than 1 race, and 5 (11%) were of unknown race. Thirty-three (72%) were men and 13 (28%) were women. High-risk cytogenetic abnormalities were present in 22 (48%) patients. The rate of sCR and\/or MRD-negativity after C8 was 26 of 45 (58%), meeting the predefined statistical threshold for efficacy. Responses deepened over time, with the MRD-negativity (10\u22125<\/jats:sup>) rate increasing to 70% and MS-negativity rate increasing to 65%; concordance between MRD by NGS and MS increased over time. The most common (&gt;10%) grade 3 or 4 adverse events were lung and nonpulmonary infections (13% and 11%, respectively). There was 1 grade 5 myocardial infarction. The estimated 3-year PFS was 72% overall and 92% for patients with MRD-negativity (10\u22125<\/jats:sup>) at C8.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>An MRD-adapted design using elotuzumab and weekly KRd without ASCT showed a high rate of sCR and\/or MRD-negativity and durable responses. This approach provides support for further evaluation of MRD-guided deescalation of therapy to decrease treatment exposure while sustaining deep responses.<\/jats:p><\/jats:sec>Trial Registration<\/jats:title>ClinicalTrials.gov Identifier: NCT02969837<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoncol.2022.2424","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T15:01:03Z","timestamp":1658415663000},"page":"1278","source":"Crossref","is-referenced-by-count":38,"title":["Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent"],"prefix":"10.1001","volume":"8","author":[{"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kansagra","sequence":"additional","affiliation":[{"name":"Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Zonder","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew T.","family":"Stefka","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Grinblatt","sequence":"additional","affiliation":[{"name":"NorthShore University Health Systems, Evanston, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandeep","family":"Gurbuxani","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Narula","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shayan","family":"Rayani","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Major","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Kin","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Jiang","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jagoda","family":"Jasielec","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"14","key":"coi220031r1","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma.","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"12","key":"coi220031r2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9","key":"coi220031r3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"issue":"22","key":"coi220031r4","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma.","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"coi220031r5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021010744","article-title":"Upfront carfilzomib, lenalidomide, dexamethasone with transplant in multiple myeloma patients, the IFM KRd final results.","author":"Roussel","year":"2021","journal-title":"Blood"},{"issue":"10","key":"coi220031r6","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"coi220031r7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30635-5","article-title":"Treatments for newly diagnosed multiple myeloma: when endurance is interrupted.","volume":"21","author":"Landgren","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10192","key":"coi220031r8","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"coi220031r9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"6","key":"coi220031r10","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial.","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"coi220031r11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma.","author":"Costa","journal-title":"J Clin Oncol"},{"issue":"10","key":"coi220031r12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.clml.2021.05.017","article-title":"Daratumumab plus carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.","volume":"21","author":"Jakubowiak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"coi220031r13","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","article-title":"Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10","key":"coi220031r14","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma.","volume":"31","author":"Flores-Montero","year":"2017","journal-title":"Leukemia"},{"issue":"3","key":"coi220031r15","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1021\/pr400985k","article-title":"Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy.","volume":"13","author":"Barnidge","year":"2014","journal-title":"J Proteome Res"},{"issue":"8","key":"coi220031r16","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"coi220031r17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials.","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"issue":"11","key":"coi220031r18","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response.","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"issue":"12","key":"coi220031r19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1001\/jamaoncol.2018.5457","article-title":"Remission and progression-free survival in patients with newly diagnosed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone: five-year follow-up of a phase 2 clinical trial.","volume":"4","author":"Kazandjian","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"coi220031r20","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41408-021-00418-2","article-title":"Measurable residual disease assessed by mass spectrometry in peripheral blood in multiple myeloma in a phase II trial of carfilzomib, lenalidomide, dexamethasone and autologous stem cell transplantation.","volume":"11","author":"Derman","year":"2021","journal-title":"Blood Cancer J"},{"issue":"2","key":"coi220031r21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41408-022-00624-6","article-title":"Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 \/07LT).","volume":"12","author":"Dispenzieri","year":"2022","journal-title":"Blood Cancer J"},{"key":"coi220031r22","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2021-149024","article-title":"Daratumumab (DARA) plus lenalidomide, bortezomib, and dexamethasone (RVd) in patients (Pts) with transplant-eligible newly diagnosed multiple myeloma (NDMM): updated analysis of Griffin after 24 months of maintenance.","volume":"138","author":"Laubach","year":"2021","journal-title":"Blood"},{"issue":"1","key":"coi220031r23","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol"},{"issue":"1","key":"coi220031r24","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1186\/s12885-019-5600-x","article-title":"Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction\/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.","volume":"19","author":"Salwender","year":"2019","journal-title":"BMC Cancer"},{"key":"coi220031r25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 Trial.","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"25","key":"coi220031r26","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: a pooled analysis of three PETHEMA\/GEM clinical trials.","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"coi220031r27","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma.","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"15","key":"coi220031r28","doi-asserted-by":"publisher","first-page":"e20005","DOI":"10.1200\/JCO.2018.36.15_suppl.e20005","article-title":"Risks of upper respiratory tract infection and pneumonia in patients with multiple myeloma receiving daratumumab: a systematic review and meta-analysis of randomized controlled trials.","volume":"36","author":"Ticona","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"coi220031r29","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.1111\/bjh.v192.3","article-title":"Sex differences in outcomes in multiple myeloma.","volume":"192","author":"Derman","year":"2021","journal-title":"Br J Haematol"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2794630\/jamaoncology_derman_2022_oi_220031_1663179785.91462.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T15:06:44Z","timestamp":1663254404000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2794630"}},"subtitle":["A Phase 2 Measurable Residual Disease\u2013Adapted Study"],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2022.2424","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}